Cencora

NYSE COR

Cencora Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: 5.16

Cencora Debt to Equity Ratio is 5.16 for the Trailing 12 Months (TTM) ending September 30, 2024, a -44.98% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Cencora Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 9.38, a -61.58% change year over year.
  • Cencora Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 24.42, a 174.00% change year over year.
  • Cencora Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -32.99, a -1,967.97% change year over year.
  • Cencora Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was 1.77, a 23.20% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
NYSE: COR

Cencora

CEO Dr. Robert P. Mauch Ph.D., PharmD
IPO Date April 4, 1995
Location United States
Headquarters 1 West First Avenue
Employees 46,000
Sector Health Care
Industries
Description

Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

StockViz Staff

January 15, 2025

Any question? Send us an email